Metagenomi

Phase A — Understand the business

Lens 1 · Company Overview

Metagenomi is an in vivo genome-editing biotech founded on metagenomics — mining genetic material from environmental samples to discover novel gene-editing enzymes beyond the standard CRISPR/Cas9 toolkit. It claims "over 20,000 signature gene editing systems" generated from its proprietary metagenomics database. The toolbox spans programmable nucleases (incl. ultra-small "SMART" nucleases that fit in AAV), base editors (7-plex demonstrated in T-cells), RNA-mediated integration systems (RIGS, first reported targeted integration of >900 bp via all-RNA delivery), and CAST systems (CRISPR-associated transposases for >10,000 bp DNA insertion; published in Nature Communications, March 2025).

This is a pre-revenue, pre-clinical company. It has never dosed a human and does not expect to until 2027. All revenue to date is collaboration revenue (deferred upfront recognition), not product sales. The business model is two-pronged:

1. Wholly-owned lead: MGX-001, a one-time in vivo editing treatment for hemophilia A — insert a B-domain-deleted Factor VIII (FVIII) cassette into the albumin safe-harbor locus in hepatocytes (AAV delivers promoterless FVIII donor; LNP delivers the MG29-1 nuclease mRNA + sgRNA). The pitch vs. episomal gene therapy: expression driven off the native albumin promoter "is unlikely to be silenced," so durable where Roctavian declines.
2. Partnered platform monetization: the Ionis collaboration (4 cardiometabolic knockdown targets) plus opportunistic out-licensing.

Corporate posture changed materially in late 2025–early 2026 (the central fact of this dossier): in Q4 2025 the company announced a "strategic evolution" — 25% workforce reduction, shelving of early discovery/platform research, CEO change (founder Brian Thomas → President/COO Jian Irish), new board chair (Willard Dere), and runway extension into Q4 2027. In Q1 2026 it renamed to Metagenomi Therapeutics, Inc. to signal the pivot from platform to clinical pipeline. This is a company that has consciously contracted to a single-asset survival posture.

• Customers: none (no product). The only "customers" are collaboration counterparties — Ionis (active), Affini-T (terminated Sept 2025, bankrupt), Moderna (terminated Apr 2024). customers.csv is empty — correct, there are none.
• Suppliers: in-house cGMP facility for nucleases + mRNA; CMOs for gRNA and DNA-template supply; Acuitas for LNP technology (non-exclusive license signed Sept 29, 2025; $3.0M upfront expensed).
• HQ: Emeryville, CA (75,662 sq ft sublease, term to March 2031, plus two additional Park Ave leases).
• Shares: 37,620,530 outstanding as of March 2, 2026.

Lens 2 · Supply Chain

For a development-stage editing company the "supply chain" is the drug-component manufacturing stack that must reach cGMP for an IND. Named stakeholders along the MGX-001 chain:

Downstream: there is no commercial channel. For partnered cardiometabolic assets, Ionis owns development and commercialization post candidate-nomination; Metagenomi manufactures licensed systems/components for Ionis at cost-plus-15%. The single most fragile link is the Acuitas LNP dependency (one target, non-exclusive, ongoing fees) layered on AAV manufacturing scarcity — both are classic genetic-medicine chokepoints and neither is owned.

Lens 3 · Competitive Advantages (moats)

The claimed moat is a proprietary enzyme-discovery engine + IP estate, not a product or a brand (there is no product). Assessment:

• Enzyme diversity / IP estate — the real, if unproven, edge. 20,000+ signature systems and a metagenomics database the company says creates "a significant barrier to entry," reinforced by trade secrets, owned patents, and 11+ PCT applications. The differentiation thesis: novel nucleases with high specificity (claimed no detectable off-target editing for MGX-001 across orthogonal assays), ultra-compact SMART nucleases that fit in AAV for extrahepatic delivery (muscle, CNS) — the one capability that, if real, addresses targets the liver-only editors (Intellia, Verve) cannot. CAST/RIGS large-insertion capability is genuinely differentiated science.
• The moat is unmonetized and unvalidated in humans. A platform moat that has never produced a clinical candidate is a hypothesis. The market is full of "novel enzyme" stories (Arbor, Scribe, Mammoth, Tessera) — discovery breadth has not historically translated to durable equity value absent a clinical win.
• Bargaining power: weak in every direction. As a $45M-cap, cash-runway-constrained microcap, MGX has minimal leverage over partners. The Ionis deal is structurally Ionis-favorable: Ionis can substitute up to two Wave-1 targets, terminate for convenience on 90 days' notice, and controls development/commercialization; MGX manufactures at cost-plus-15%. Acuitas can terminate in specified situations. Suppliers (CMOs, Acuitas) hold the cards.
• Switching costs / network effects / scale: none of the classic moats apply at this stage. The only durable asset is the patent estate + trade secrets, and patent positions in genome editing are explicitly described by the company as "generally uncertain" with "no consistent policy regarding the scope of patentable claims".

Verdict on the moat: scientifically credible, commercially unproven, and currently worth less than the cash — the market is assigning the platform a negative value (see Lens 11). The SMART-nuclease extrahepatic capability is the one piece a strategic acquirer might actually pay for.

Lens 4 · Segments

One reportable segment — "developing curative therapeutics … using the Company's proprietary, comprehensive metagenomics-derived genome editing toolbox." All long-lived assets and all revenue are U.S.-based; the CODM (CEO) manages on net loss. segments.csv is empty — correct; there is no product-segment or geographic split to populate.

The only available decomposition is collaboration revenue by partner:

The trend is sharp deceleration — collaboration revenue fell $27.1M (−52%) YoY, driven by the Moderna termination ($18.7M of deferred-revenue burn-off in 2024) and lower Ionis work-performed. Q1 2026 collaboration revenue was just $1.25M, down 70% YoY (Q1'25 $4.13M), with Affini-T now at zero. The "revenue" line is decaying toward zero as the Ionis upfront fully amortizes; this company's reported revenue is an accounting artifact of past upfronts, not a growth signal.

---

Phase B — Measure performance (clinical overlay)

Lens 5 · Pipeline by phase (swapped from Earnings Result)

The asset table is the company. Every program is preclinical or earlier — Metagenomi has zero clinical-stage assets and no IND filed yet.

MGX-001 NHP data quality (the bull's whole case):

• Dose-range-finding study (Nov 2025): 24 NHPs, 6 AAV cohorts (5.0e11–4.0e13 vg/kg) + variable LNP (0.2/0.6/2.0 mg/kg).
• At fixed 0.6 mg/kg LNP + 1.6e12–4e13 AAV: average per-cohort FVIII activity 49%–81% ("curative" defined as 50–150% of normal). No animal exceeded 150%.
• Earlier study: durable FVIII over a ~19-month NHP study; no detectable off-target editing across orthogonal assays.
• Well tolerated except transient liver-enzyme elevations at the highest LNP dose.

This is a genuinely encouraging preclinical package — durable, dose-dependent, on-target, in primates. The problem is everything downstream of it (Lens 12). Lens 5 verdict: a credible single preclinical asset and a credible second indication (AT-III), entirely NHP-stage, with the first human dosing 12+ months away and no human efficacy/safety read before ~2028.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty; the ingest tooling cannot scrape MGX's IR PDF transcripts cleanly — a known limitation). Sentiment read is therefore ``-derived from the corporate-communications record:

• Through 2024: post-IPO optimism collapsed fast. The Moderna termination (May 2024) — disclosed weeks after the Feb 2024 IPO that had partly sold the Moderna relationship — was the credibility break and is the factual basis of the securities class action (Lens 10).
• Through 2025: tone shifted from "broad platform" to "focus and survive." The Q4 2025 restructuring messaging is explicitly defensive — "maintaining financial discipline," "highest probability of success," runway extension.
• 2026: management language is narrowly milestone-driven (pre-IND complete, IND Q4'26, FIH 2027) and partnership-hopeful ("seeking enabling partnerships and business development opportunities"). The things they stopped saying: Moderna, broad multi-program platform expansion, near-term clinical breadth. The recurring new phrase: "wholly-owned MGX-001 … highest probability of success." This is the vocabulary of a company husbanding cash to a single shot on goal.

Lens 7 · Catalyst calendar + mechanism comps (swapped from Comps)

Catalyst calendar — what de-risks or kills the story, and when:

The fatal structural feature: the runway (Q4'27) ends roughly two years before the first human efficacy data that would actually re-rate the equity. Management must raise or partner from a position of weakness in 2026–27, into a hostile market, with a single preclinical asset.

Mechanism comps (by approach, not P/E — pre-revenue peers):

P/E, EV/Sales, EV/EBIT, dividend yield, 5-yr avg ROE: n/a / not meaningful. Every name here is pre-revenue and loss-making; conventional multiples do not exist and a fabricated one would be the worst possible output here. The only comparable metric that matters is EV/cash and proximity-to-clinic, and on both MGX screens worst-in-class: it has the least-advanced lead asset and a negative enterprise value. Intellia (BLA filed) shows what a de-risked in-vivo editor is worth; MGX shows what an undatad one is worth after an IPO break.

Lens 8 · Stock-Price Catalysts (what moves it, last ~2.5 yrs as a public co.)

MGX has only traded since Feb 2024, so the 5-year window is its entire public life:

• IPO Feb 9–13, 2024 @ $15.00, 6.25M shares, $93.75M gross. ATH $12.74 on Feb 15, 2024 (never traded materially above issue).
• Moderna termination (May 1, 2024): major down-leg; the event that seeded the class action. The market reacted violently to losing a marquee partner weeks post-IPO.
• Q4 2025 restructuring / CEO change / 25% layoff (Nov 2025): "shares fall" — the market read the focus-and-cut as distress, not discipline.
• Q1 2026 print (May 2026): revenue missed by ~79% (vs the now-trivial estimate); reinforced the "revenue going to zero" read.
• All-time low $1.20 on Jun 12, 2026 — the stock is at/near its nadir as of this dossier.
• Founder Brian Thomas resigns from board (Jun 9, 2026) — "not due to disagreement," but the founder fully exiting a $45M-cap shell is a sentiment negative.

Pattern: MGX trades on binary platform-credibility events (partner loss, restructuring, governance) far more than on financials. There has been no positive catalyst large enough to re-rate it since the IPO; every material move has been down. The market reacts to survival probability, and currently prices it low. The next true catalyst is the Q4 2026 IND — and even a clean IND only buys the right to spend cash it doesn't have toward a 2028 readout.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO — Jian Irish, Ph.D., M.B.A. (since Q4 2025). Former President/COO of Metagenomi; prior development and global-operations roles at Kite Pharma/Gilead, Sanofi, and Amgen, with a hand in launching breakthrough medicines. A credible operator-archetype CEO installed precisely to execute a disciplined, capital-constrained clinical push — the right profile for this moment, though notably an operator, not the scientific founder.
• Founder — Brian Thomas, Ph.D. (former CEO): stepped down to the board in the Q4 2025 reshuffle, then resigned from the board entirely effective June 9, 2026. The scientific founder's complete departure from a microcap he took public ~28 months earlier is a material signal — at minimum it removes the technology's chief evangelist from governance.
• Board chair — Willard Dere, M.D. (new, Q4 2025). Other directors: Eric Bjerkholt (CFO-archetype/biotech finance), Jürgen Eckhardt, M.D. (ex-Bayer/Leaps BD background), Laurence Reid, Ph.D. (seasoned biotech CEO/board operator). A finance/BD-weighted board — consistent with a company whose next moves are a raise, a partnership, or a sale.
• Track record / capital allocation: the available record is poor as a public company. Raised ~$351.7M in private preferred + $80.7M net IPO + ~$120M collaboration upfronts, and has spent its way to a $310.9M accumulated deficit with no clinical asset and a market cap below cash. To the new team's credit, the 25% cut + discovery-shelving + runway extension is the correct defensive allocation; they are husbanding the remaining cash toward the one asset with NHP data. ROE/ROIC are deeply negative and not meaningful for a pre-revenue burner.
• Skin in the game / insider ownership: detailed beneficial-ownership figures are incorporated by reference to the 2026 proxy (DEF 14A), not in the 10-K body; precise insider % n/a in this pass. A CEO open-market sale of ~$2,899 was reported — immaterial in size (likely tax/auto), but no insider buying signal at a sub-cash price, which itself is telling. Public float was only $50,931,318 as of June 30, 2025, implying the large majority of shares sit with insiders/pre-IPO VCs — a thin, illiquid microcap.
• Founder vs. professional manager: decisively pivoted from founder-led to professional-manager-led (Irish) with the founder gone. For a company whose forward path is execution-and-monetization rather than discovery, that archetype shift is arguably appropriate — but it also reads as the VC syndicate taking control of an asset to preserve value, not a visionary scaling a platform.

Lens 10 · Forensic Red Flags

Accounting itself is clean and simple — there is no revenue to manipulate and the structure is a standard pre-revenue burn:

• Revenue recognition: collaboration revenue is deferred-upfront amortization (ASC 606), fully consistent across periods; the decline is real economics (Moderna/Affini-T gone, Ionis amortizing out), not a recognition trick.
• Cash vs. earnings: FY2025 net loss $87.9M vs. operating cash burn $88.9M — they track tightly (no accrual divergence). Investing cash inflow of $103.5M in FY2025 is just securities maturing into cash, not a red flag.
• SBC: R&D-related SBC $4.8M and total non-cash SBC $11.9M in FY2025 (down YoY on headcount cuts); $15.2M unrecognized SBC at Q1'26 ($2.5M RSA + $8.4M options + $4.3M RSU) — modest, not flattering any non-GAAP metric (the company reports GAAP losses).
• Receivables/inventory vs. revenue: no inventory (no product); receivables are immaterial and declining. No working-capital red flags.
• Investments: the Affini-T equity stake was written down ($1.3M FV loss FY2025; $9.2M FY2024) and the relationship is terminated — already cleaned up.
• Going concern: management asserts the $140.2M funds operations "for at least the next 12 months" with runway into Q4 2027; no going-concern qualification is disclosed, but the substantial-additional-funding risk is front-and-center. For a +clinical name the dilution/financing risk is the dominant "forensic" exposure: an ATM facility of $75M with Jefferies is in place and unused as of Q1'26 — a standing dilution mechanism at a sub-cash price.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. No LR or AAER names Metagenomi (SEC EDGAR EFTS, search period 2021-06-30 to 2026-06-30).
• Securities class action — MATERIAL, AND IT SURVIVED DISMISSAL. Vreeland v. Metagenomi Inc. et al., No. 5:24-cv-06765 (N.D. Cal., filed Sept 26, 2024). Alleges Section 11 (Securities Act) violations against all defendants and Section 15 control-person violations against individual officers/directors, claiming misleading statements and omissions about the Moderna collaboration in the Jan/Feb 2024 IPO registration statement and prospectus. Lead plaintiff appointed Feb 10, 2025; amended complaint Apr 4, 2025; defendants moved to dismiss May 16, 2025. On March 24, 2026, the court granted-in-part and denied-in-part the motion to dismiss — i.e., the case proceeds. Defendants' response to the operative complaint was due May 27, 2026. Company "intends to defend vigorously"; outcome and loss range not estimable. This is a live Section 11 case that has cleared the pleading stage — a real, ongoing legal and reputational overhang for a company whose IPO-era disclosures are exactly what is at issue.
• Non-SEC enforcement (FTC/DOJ/FDA/CFPB): None found. No warning letters, settlements, fines, or consent decrees surfaced for Metagenomi.
• Summary: No accounting-enforcement or non-SEC regulatory findings as of 2026-06-30 (verified via SEC EDGAR EFTS LR/AAER, web search, and 10-K Item 3 / 10-Q Note 8). The one material legal item is the surviving Vreeland Section 11 securities class action.

---

Phase D — Project & stress-test

Lens 11 · rNPV + runway-to-catalyst (swapped from Forward Projection)

No EPS projection — this is pre-revenue; EPS is loss-per-share for years. The two questions that matter are (a) what is the risk-adjusted value of the lead asset, and (b) does the cash reach the next value-inflection catalyst? It does not.

Runway-to-catalyst (the decisive call):

• Cash/equiv/securities $140.2M at Mar 31, 2026; gross quarterly cash decline ~$20.6M (Dec'25 $160.8M → Mar'26 $140.2M); operating burn FY2025 $88.9M ≈ ~$22M/quarter.
• Management guides runway into Q4 2027 (the 25% cut funds ~2 more years).
• IND: Q4 2026. FIH dosing: 2027. First human FVIII-activity readout: ~2028 at the earliest (a one-time editing trial reads out durably only after months of follow-up).
• Therefore the runway exhausts BEFORE the catalyst that re-rates the equity. The company must raise (likely via the $75M Jefferies ATM and/or a follow-on, both dilutive at ~$1.20) or strike a partnership/M&A from weakness, sometime in 2026–2027. This is the single most important output of the battery: the cash does not reach the value-inflection, so dilution or a deal is near-certain before any human-efficacy print.

rNPV of MGX-001 (lead asset) — ``, illustrative, every input labeled:

• Hemophilia A epidemiology: ~26,500 US patients, ~500,000 global, ~60% severe.
• Addressable peak revenue is the crux and is collapsing: hemophilia-A gene therapy has a demonstrated commercial-failure precedent — Roctavian's projected $2.2B peak delivered ~$23–26M/yr before BioMarin withdrew it from the US (May 2026). A rational unrisked peak for a best-in-class durable one-time editor is therefore modest — assume $300–600M global peak `` (well below the old gene-therapy dreams, reflecting payer resistance and competition from Hemlibra/Altuviiio/Alhemo/Hympavzi).
• Probability of success from preclinical (no human data) for a novel-modality, novel-target-delivery gene-editing product: ~5–10% `` (preclinical-to-approval base rates for novel genetic medicines are in the low single-to-high-single digits; MGX-001's strong NHP package + well-understood FVIII biomarker argues the top of that range).
• Illustrative rNPV: $450M peak × ~8% PoS × a ~5–7-yr-to-launch discount (assume cumulative ~0.45 factor at a biotech-appropriate 12% rate) ≈ **$15–20M risk-adjusted, pre-dilution **. Add AT-III + other secreted-protein optionality and the Ionis royalty/milestone stream (low-teens royalties + up to $339M/product in milestones, heavily PoS-discounted) and a generous all-in lead-program-plus-platform rNPV lands in a **~$30–80M range ** — strikingly close to the current $45–50M market cap, which is why the equity trades at roughly cash: the market assigns the risk-adjusted pipeline almost no value beyond the balance sheet.
• Brier forecast (logged conceptually; forecast.ts create SKIPPED per --watchlist rule): the trackable binary is "MGX-001 IND accepted/cleared by FDA by 2027-06-30," base-rate-anchored at p≈0.70 (pre-IND complete + clean NHP tox + standard pathway argue acceptance is likelier than not; the risk is timing/CMC, not concept).

Lens 12 · Bull vs Bear (adversarial)

Bull case. The science is real and de-risking: durable (~19-month NHP), dose-dependent, on-target FVIII at curative levels (49–81%), differentiated from episomal gene therapy by native-promoter durability. The SMART-nuclease/CAST/RIGS platform genuinely extends editing beyond the liver and to large-gene insertion — capabilities the CRISPR/Cas9 leaders lack. In-vivo editing as a category is being validated by others right now (Intellia's lonvo-z BLA; Lilly/Verve's VERVE-102 PCSK9 win), de-risking the modality if not the asset. And the entry price is extraordinary: you are paying ~$45M for ~$140M of cash plus a free option on a clinical-stage editing platform — a roughly −$90M enterprise value. A single positive event — IND clearance, an Ionis Wave-2 trigger, or (most plausibly) a strategic acquisition of the platform/asset — could multiply the equity from a sub-cash base. With ~37.6M shares and a tight float, any re-rating is violent.

Bear case (2–3 permanent-impairment risks).

1. The end market is commercially broken, independent of whether the drug works. Hemophilia A one-time therapies are a graveyard: Roctavian withdrawn from the US after a $240M write-off and a failed divestiture; Pfizer pulled Beqvez (hem B); incumbents Hemlibra/Altuviiio/Alhemo/Hympavzi own the market with convenient, de-risked prophylaxis. Even a clinically successful MGX-001 inherits a market that has repeatedly rejected the "once-and-done" value proposition. This caps the upside permanently.
2. The financing cliff precedes the proof. Runway dies Q4'27; first human efficacy ~2028. The company must dilute (sub-$1.20 ATM) or sell from weakness before it can prove anything — structural, near-certain value transfer away from current holders.
3. Single-asset, novel-modality binary with a live Section 11 suit. One wholly-owned preclinical program, a novel nuclease (MG29-1) with no human safety, in a field where a peer (Intellia) had a patient death raising Cas-class safety questions — and a securities class action that survived dismissal hanging over the same IPO-era story. Any one of these can permanently impair.

Pre-mortem (it's late 2027, the thesis broke — what happened?). Most likely: the IND slipped or cleared but the company hit the runway wall and did a deeply dilutive raise / fire-sale partnership at sub-cash; OR the first-in-human dosing surfaced an LNP/AAV tolerability or immunogenicity signal (the highest-dose transient transaminase elevations foreshadow this); OR the Vreeland case + a hostile biotech tape simply made the cost of capital prohibitive and the board sold the asset for the cash. The platform "worked" in NHPs and still lost equity value because cash mechanics and end-market economics, not science, governed the outcome.

Are multiples too high? No — there are no earnings multiples, and the equity already trades below cash. The market is not over-paying; if anything it prices a non-trivial chance of value destruction via dilution.

Contrarian view (what the market refuses to see). The market is treating MGX as a slow-motion liquidation. The contrarian read is that it is a cleaned-up, focused asset-shell with a tier-1-operator CEO, a finance/BD board, $140M of cash, a non-dilutive Ionis royalty tail, and a differentiated extrahepatic-editing platform — i.e., precisely the package a larger editing/genetic-medicine player would acquire for the IP and the cash. The bet that pays is M&A/strategic-control, not clinical success. That is a real, if low-probability, optionality the sub-cash price gives you almost for free.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• "Below cash" is a value trap if the cash is consumed before value is created. A pre-revenue biotech burning ~$22M/quarter with a 2028 catalyst and a Q4'27 runway is designed to convert that cash into losses; the "discount to cash" narrows every quarter by the burn and resets lower with each dilutive raise. Buying sub-cash biotechs systematically underperforms unless a hard catalyst (buyout, positive data) lands fast — here the catalyst is years out.
• Revenue is going to zero and the only partner can walk on 90 days' notice. Collaboration revenue −70% YoY to $1.25M in Q1'26; Ionis controls economics, can substitute targets and terminate for convenience. The "platform monetization" leg is a thin reed.
• The moat is unproven and the field is crowded with better-funded enzyme stories. Arbor, Scribe, Mammoth, Tessera (private) and Beam/Intellia/Prime (public, clinical) are all hunting the same ground with more capital and, in several cases, actual human data. "20,000 systems" is a slide, not a clinical candidate.
• Most dangerous competitor bulls underestimate: not the other editors — it's the incumbent non-gene-therapy standard of care (Roche's Hemlibra/emicizumab, Sanofi's Altuviiio, Novo's Alhemo, Pfizer's Hympavzi). They are convenient, de-risked, and have already beaten one-time gene therapy in the market. MGX-001's competition isn't Roctavian — it's the drugs that killed Roctavian.
• Worst capital-allocation reality: $310.9M accumulated deficit, IPO at $15 now ~$1.20 (−92%), a marquee partner (Moderna) lost weeks after listing, founder departed, and a Section 11 suit that survived dismissal alleging the IPO story was misleading. That is a value-destruction track record, even granting the new team's defensive discipline.
• What must hold for today's ~$45M price: essentially that the company doesn't destroy the cash — i.e., it gets acquired or strikes a strong partnership before the runway/dilution does damage. If instead it taps the $75M ATM at sub-$1.20 and grinds toward 2028, the per-share value erodes regardless of the science.
• If growth/PoS disappoints by 20–30%: there is no "growth" to disappoint; the sensitivity is binary — an IND delay, a clinical-hold-type safety read (cf. Intellia's patient death and ATTR hold), or a failed financing each independently re-rates the equity toward cash-minus-burn.
• Single scenario that permanently impairs: a first-in-human (2027–28) tolerability/immunogenicity signal on the LNP/nuclease that triggers a hold — plausible given the highest-dose transaminase elevations and the Cas-class safety questions now circulating industry-wide. Plausibility: moderate.

Lens 14 · Management Questions (ordered by information value)

1. Runway vs. catalyst: the runway ends Q4 2027 but the first human FVIII-activity readout is ~2028 — exactly how do you intend to bridge that gap (ATM, follow-on, partnership, or sale), and at what point do you decide between dilution and a strategic transaction?
2. Dilution at sub-cash: with the stock below net cash, under what conditions would you actually draw on the $75M Jefferies ATM, and how do you reconcile issuing equity at ~$1.20 with fiduciary duty to current holders?
3. Strategic alternatives: has the board run, or will it run, a formal process to evaluate a sale of the company or the MGX-001 asset given that the market assigns the pipeline negative value?
4. MGX-001 differentiation that pays: beyond durability, what specific clinical-economic edge will let MGX-001 succeed commercially where Roctavian was withdrawn from the US market — i.e., why does a one-time hemophilia A therapy work this time?
5. Safety read-across: given Intellia's reported patient death and Cas-class safety scrutiny, and your own highest-dose transaminase elevations in NHPs, what is your immunogenicity/hepatotoxicity de-risking plan for first-in-human?
6. IND specifics: what is the gating risk for the Q4 2026 IND — CMC/manufacturing readiness, tox package, or chemistry — and what is the realistic probability and timeline to FDA clearance?
7. Ionis economics: what is the realistic timeline to first candidate nomination under Ionis Wave 1, and how likely is a Wave-2 trigger (and its $15–30M target fees) within the runway window?
8. Founder departure: what should investors infer from founder Brian Thomas's complete exit from the board in June 2026, and what changed in the scientific direction as a result?
9. Platform monetization: with discovery research shelved, how do you preserve and eventually monetize the 20,000-system platform and the SMART/CAST/RIGS IP — out-license, spin-out, or hold?
10. Litigation: now that the Vreeland Section 11 claims have survived dismissal, what is your realistic exposure range and how much management time and cash will the defense consume through 2027?
11. Extrahepatic proof: when will you generate in vivo proof-of-concept for a non-liver target (muscle/CNS) using SMART nucleases — the capability that actually differentiates you from Intellia/Verve?
12. Capital efficiency: post-restructuring, what is your steady-state quarterly burn, and what is the minimum cash you need to reach the first human efficacy readout?
13. AT-III and second indications: which secreted-protein-deficiency indication is the strongest second wholly-owned program, and would you partner it to fund MGX-001?
14. Manufacturing dependencies: how exposed are you to the single-target, non-exclusive Acuitas LNP license and to AAV manufacturing capacity, and what is the plan to internalize or diversify delivery?
15. Definition of success: 24 months out, what specific milestones would constitute success for shareholders at this valuation, and what would trigger a wind-down or return of capital?

---